U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H13N
Molecular Weight 159.2276
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PARGYLINE

SMILES

CN(CC#C)CC1=CC=CC=C1

InChI

InChIKey=DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3

HIDE SMILES / InChI

Molecular Formula C11H13N
Molecular Weight 159.2276
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pargyline is an irreversible selective monoamine oxidase (MAO)-B inhibitor, which possesses higher selectivity to this isoform in comparison with MAO-A. It was approved under brand name eutonyl for the treatment hypertension, but then this drug was discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Eutonyl

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
272 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.
1984 Sep
[Effects of pentoxifylline on 5-hydroxytryptamine in the mouse brain].
1985 Nov
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats.
1985 Oct
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
1987 Sep
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.
1994 Jul 11
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:11:57 GMT 2023
Edited
by admin
on Fri Dec 15 16:11:57 GMT 2023
Record UNII
9MV14S8G3E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PARGYLINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BENZENEMETHANAMINE, N-METHYL-N-2-PROPYNYL-
Systematic Name English
pargyline [INN]
Common Name English
Pargyline [WHO-DD]
Common Name English
PARGYLINE [MI]
Common Name English
PARGYLINE [VANDF]
Common Name English
N-METHYL-N-2-PROPYNYLBENZYLAMINE
Systematic Name English
Classification Tree Code System Code
WHO-ATC C02LL01
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
NCI_THESAURUS C270
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
WHO-VATC QC02LL01
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
NCI_THESAURUS C667
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
WHO-VATC QC02KC01
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
WHO-ATC C02KC01
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
Code System Code Type Description
DRUG BANK
DB01626
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
IUPHAR
7262
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
DRUG CENTRAL
2065
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID3023423
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
CAS
555-57-7
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
SMS_ID
100000082797
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
FDA UNII
9MV14S8G3E
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
INN
1350
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
MESH
D010293
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
ECHA (EC/EINECS)
209-101-6
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
MERCK INDEX
m8412
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY Merck Index
PUBCHEM
4688
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
RXCUI
7930
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C66322
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
EVMPD
SUB09626MIG
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
WIKIPEDIA
PARGYLINE
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL673
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY